Trusted Resource for Clinical Trials, Protocols & Progress
The International Council for Harmonisation (ICH) introduced Good Clinical Practice (GCP) guidelines to harmonize ethical and scientific standards for clinical trials globally. The most widely applied guideline—ICH E6(R2), and the evolving E6(R3)—sets expectations for sponsors, investigators, and CROs regarding the conduct, monitoring, recording, and reporting of trials.
Click to read the full article.
Safety narratives are integral components of pharmacovigilance reporting, providing a detailed description of individual Serious Adverse Events (SAEs) or Suspected Unexpected Serious Adverse Reactions (SUSARs). They include clinical context, chronology, medical assessments, and outcomes, enabling regulators to evaluate causality and risk.
Click to read the full article.
Clinical trial inspections are critical mechanisms used by regulatory authorities such as the FDA, EMA, MHRA, and PMDA to evaluate compliance with ICH GCP, regional laws, and ethical standards. Findings from these inspections directly impact a sponsor’s ability to secure regulatory approvals and maintain credibility. For sponsors, inspection readiness is not a one-time exercise but a continuous obligation throughout the lifecycle of a clinical trial.
Click to read the full article.
Clinical trials progress through distinct phases, each with unique objectives, designs, and regulatory scrutiny. Phase I trials typically involve a small number of healthy volunteers or patients to evaluate safety, tolerability, and pharmacokinetics. In contrast, Phase III trials enroll large patient populations to confirm efficacy and monitor adverse events at scale. Regulatory authorities such as the FDA, EMA, and MHRA adjust their inspection strategies depending on the trial phase, leading to different patterns of audit findings.
Click to read the full article.
Pharmacovigilance signal detection is a systematic process of identifying new or changing safety issues related to an investigational product. Regulators such as the FDA, EMA, and MHRA mandate continuous monitoring of adverse event data to detect potential signals early and implement risk mitigation measures. Signal detection reporting must be timely, accurate, and comprehensive to protect participants and ensure regulatory compliance.
Click to read the full article.
Multicenter clinical trials offer sponsors the ability to enroll large, diverse patient populations across different geographies, enhancing the statistical power and generalizability of study results. However, the complexity of coordinating numerous sites introduces significant compliance risks. Regulatory authorities such as the FDA, EMA, and MHRA consistently report higher rates of audit findings in multicenter studies compared to single-site trials.
Click to read the full article.
Sponsors bear ultimate responsibility for the safety of investigational products, regardless of whether pharmacovigilance activities are delegated to a Contract Research Organization (CRO). Oversight of Serious Adverse Events (SAEs), Suspected Unexpected Serious Adverse Reactions (SUSARs), and annual safety submissions such as the Development Safety Update Report (DSUR) must be proactive, continuous, and verifiable.
Click to read the full article.
Over the past decade, clinical trial inspections have evolved significantly as regulatory agencies adapt to new challenges, technologies, and trial designs. The FDA, EMA, MHRA, and PMDA have emphasized transparency, data integrity, and patient safety as core priorities. More recently, the COVID-19 pandemic and the rise of decentralized clinical trials (DCTs) have reshaped inspection practices, resulting in new patterns of audit findings.
Click to read the full article.
Serious Adverse Event (SAE) reconciliation is the process of ensuring that safety data recorded at investigator sites is consistent with sponsor pharmacovigilance databases. It is a fundamental expectation of ICH E2A, FDA, and EMA regulatory frameworks. The goal is to confirm that all SAEs documented in Case Report Forms (CRFs) or Electronic Data Capture (EDC) systems are also reported, processed, and stored in the sponsor’s safety database.
Click to read the full article.
Regulatory audits often uncover deficiencies that shape the future of clinical trial oversight. High-impact findings not only affect individual trials but also set precedents for regulatory expectations. By analyzing case studies of significant audit findings from agencies such as the FDA, EMA, and MHRA, sponsors and sites can identify recurring pitfalls, understand root causes, and implement effective Corrective and Preventive Actions (CAPA).
Click to read the full article.
